Finasteride and methadone use and risk of advanced hepatitis C related liver disease

Digestive Diseases and Sciences

Volumn 57, Issue 11, 2012, Pages 3004-3010

  White, Donna L ^a,b,c   Hashmi, Ali ^b,c   Ramsey, David J ^a   Kuzniarek, Jill ^a   Tavakoli Tabasi, Shahriar ^b,c   Hashem B El Serag, ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug addiction; Epidemiology; Hepatology; Sex hormones; Urology

Indexed keywords

ANDROGEN; FINASTERIDE; METHADONE;

ADULT; AGED; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG USE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; VETERAN;

5-ALPHA REDUCTASE INHIBITORS; ADULT; AGED; CROSS-SECTIONAL STUDIES; FINASTERIDE; HEPATITIS C; HUMANS; LIVER DISEASES; LOGISTIC MODELS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; RISK ASSESSMENT; RISK FACTORS; TEXAS; VETERANS;

EID: 84871607859     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2231-3     Document Type: Article

References (25)

1. Yuan JM, Ross RK, Stanczyk FZ, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995;63:491-493.
2. Nguyen HV, Mollison LC, Taylor TW, Chubb SA, Yeap BB. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J. 2006;36:362-366.
3. Safarinejad MR, Kolahi AA, Iravani S. Evaluation of semen variables, sperm chromosomal abnormalities and reproductive endocrine profile in patients with chronic hepatitis C. BJU Int. 2010;105:79-86.
4. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768.
5. Centers for Disease Control and Prevention. Health, United States
6. Health resource use: table 95. Selected prescription drug classes used in the past month, by sex and age: United States, selected years 1988-1994 through 2005-2008. 2011. Atlanta, GA; CDC.
7. Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009;32:131-139.
8. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377-384.
9. de la Rosa RE, Hennessey JV. Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract. 1996;2:4-7.
10. El-Shabrawi MH, Mohsen NA, Sherif MM, et al. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol. 2010;22: 946-951.
11. Poynard T, de Ledinghen V, Zarski JP, et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol. 2012;56:541-548.
12. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207-218.
13. Poynard T, Munteanu M, Ngo Y, et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol. 2010;34:388-396.
14. Morali G, Maor Y, Klar R, et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis-the Israeli experience. Isr Med Assoc J. 2007;9:588-591.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264.
16. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43:284-292.
17. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57:1073-1077.
18. Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE. 2012;7:e30325.
19. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.
20. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE. 2011;6:e26783.
21. Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA. Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos. 2010;38:1308-1313.
22. Robertson IG, Gamage RS. Methadone: a potent inhibitor of rat liver aldehyde oxidase. Biochem Pharmacol. 1994;47:584-587.
23. Ceriello A, Giugliano D, Passariello N, et al. Impaired glucose metabolism in heroin and methadone users. Horm Metab Res. 1987;19:430-433.
24. Housova J, Wilczek H, Haluzik MM, Kremen J, Krizova J, Haluzik M. Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiol Res. 2005; 54:73-78.
25. Bacchetti P, Boylan R, Astemborski J, et al. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS ONE. 2011;6:e20104.